Knopp Biosciences' Dexpramipexole Meets Primary Endpoints in Phase 2 Trial Results in Hypereosinophilic Syndromes (HES)

Knopp Biosciences LLC  announced on 5/10/18 the publication of a report in the journal Blood that a Phase 2 study of dexpramipexole in hypereosinophilic syndromes (HES) met its co-primary endpoints.